Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide with a 5-year overall survival rate of less than 20 %. Considering the treatments currently available, this statistics is shocking. A possible explanation for the disconnect between sophisticated treatments and the survival rate can be related to the post-treatment enrichment of Cancer Stem Cells (CSCs), which is one of a sub-set of drug resistant tumor cells with abilities of self-renewal, cancer initiation, and further maintenance of tumors. Lung CSCs have been associated with resistance to radiation and chemotherapeutic treatments. CSCs have also been implicated in tumor recurrence because CSCs are not typically killed after conventional therapy. Investigation of CSCs in determining their role in tumor recurrence and drug-resistance relied heavily on the use of specific markers present in CSCs, including CD133, ALDH, ABCG2, and Nanog. Yet another cell type that is also associated with increased resistance to treatment is epithelial-to-mesenchymal transition (EMT) phenotypic cells. Through the processes of EMT, epithelial cells lose their epithelial phenotype and gain mesenchymal properties, rendering EMT phenotypic cells acquire drug-resistance. In this chapter, we will further discuss the role of microRNAs (miRNAs) especially because miRNA-based therapies are becoming attractive target with respect to therapeutic resistance and CSCs. Finally, the potential role of the natural agents and synthetic derivatives of natural compounds with anti-cancer activity, e.g. curcumin, CDF, and BR-DIM is highlighted in overcoming therapeutic resistance, suggesting that the above mentioned agents could be important for better treatment of lung cancer in combination therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Pathak AK, Bhutani M, Mohan A, Guleria R, Bal S, Kochupillai V (2004) Non small cell lung cancer (NSCLC): current status and future prospects. Indian J Chest Dis Allied Sci 46:191–203
Singh S, Chellappan S (2014) Lung cancer stem cells: molecular features and therapeutic targets. Mol Aspects Med 39:50–60
Kanwar SS, Yu Y, Nautiyal J, Patel BB, Padhye S, Sarkar FH et al (2011) Difluorinated-curcumin (CDF): a novel curcumin analog is a potent inhibitor of colon cancer stem-like cells. Pharm Res 28:827–838
Hu Y, Fu L (2012) Targeting cancer stem cells: a new therapy to cure cancer patients. Am J Cancer Res 2:340–356
Chen YC, Hsu HS, Chen YW, Tsai TH, How CK, Wang CY et al (2008) Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells. PLoS One 3, e2637
Wu Y, Wu PY (2009) CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev 18:1127–1134
Mizugaki H, Sakakibara-Konishi J, Kikuchi J, Moriya J, Hatanaka KC, Kikuchi E et al (2014) CD133 expression: a potential prognostic marker for non-small cell lung cancers. Int J Clin Oncol 19:254–259
Shien K, Toyooka S, Ichimura K, Soh J, Furukawa M, Maki Y et al (2012) Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy. Lung Cancer 77:162–167
Herpel E, Jensen K, Muley T, Warth A, Schnabel PA, Meister M et al (2011) The cancer stem cell antigens CD133, BCRP1/ABCG2 and CD117/c-KIT are not associated with prognosis in resected early-stage non-small cell lung cancer. Anticancer Res 31:4491–4500
Russo JE, Hilton J (1988) Characterization of cytosolic aldehyde dehydrogenase from cyclophosphamide resistant L1210 cells. Cancer Res 48:2963–2968
Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B et al (2010) Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 70:9937–9948
Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH et al (2013) ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett 328:144–151
Alamgeer M, Ganju V, Szczepny A, Russell PA, Prodanovic Z, Kumar B et al (2013) The prognostic significance of aldehyde dehydrogenase 1A1 (ALDH1A1) and CD133 expression in early stage non-small cell lung cancer. Thorax 68:1095–1104
Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L et al (2009) Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci U S A 106:16281–16286
Sung JM, Cho HJ, Yi H, Lee CH, Kim HS, Kim DK et al (2008) Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun 371:163–167
Dylla SJ, Beviglia L, Park IK, Chartier C, Raval J, Ngan L et al (2008) Colorectal cancer stem cells are enriched in xenogeneic tumors following chemotherapy. PLoS One 3, e2428
Li L, Yu H, Wang X, Zeng J, Li D, Lu J et al (2013) Expression of seven stem-cell-associated markers in human airway biopsy specimens obtained via fiberoptic bronchoscopy. J Exp Clin Cancer Res 32:28
Yi H, Cho HJ, Cho SM, Jo K, Park JA, Kim NH et al (2012) Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol 41:310–316
Du Y, Ma C, Wang Z, Liu Z, Liu H, Wang T (2013) Nanog, a novel prognostic marker for lung cancer. Surg Oncol 22:224–229
Rappa G, Fodstad O, Lorico A (2008) The stem cell-associated antigen CD133 (Prominin-1) is a molecular therapeutic target for metastatic melanoma. Stem Cells 26:3008–3017
Smith LM, Nesterova A, Ryan MC, Duniho S, Jonas M, Anderson M et al (2008) CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 99:100–109
Kim RJ, Park JR, Roh KJ, Choi AR, Kim SR, Kim PH et al (2013) High aldehyde dehydrogenase activity enhances stem cell features in breast cancer cells by activating hypoxia-inducible factor-2alpha. Cancer Lett 333:18–31
Stacy AE, Jansson PJ, Richardson DR (2013) Molecular pharmacology of ABCG2 and its role in chemoresistance. Mol Pharmacol 84:655–669
Mimeault M, Hauke R, Batra SK (2008) Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies. Clin Pharmacol Ther 83:673–691
Siu MK, Wong ES, Chan HY, Ngan HY, Chan KY, Cheung AN (2008) Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. Am J Pathol 173:1165–1172
Xiao D, He J (2010) Epithelial mesenchymal transition and lung cancer. J Thorac Dis 2:154–159
Trumpp A, Wiestler OD (2008) Mechanisms of disease: cancer stem cells–targeting the evil twin. Nat Clin Pract Oncol 5:337–347
Liu YP, Yang CJ, Huang MS, Yeh CT, Wu AT, Lee YC et al (2013) Cisplatin selects for multidrug-resistant CD133+ cells in lung adenocarcinoma by activating Notch signaling. Cancer Res 73:406–416
Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L et al (2006) Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res 66:944–950
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133:704–715
Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F et al (2012) EMT and dissemination precede pancreatic tumor formation. Cell 148:349–361
Zhang Y, Wei J, Wang H, Xue X, An Y, Tang D et al (2012) Epithelial mesenchymal transition correlates with CD24+ CD44+ and CD133+ cells in pancreatic cancer. Oncol Rep 27:1599–1605
Giarnieri E, De VC, Noto A, Roscilli G, Salerno G, Mariotta S et al (2013) EMT markers in lung adenocarcinoma pleural effusion spheroid cells. J Cell Physiol 228:1720–1726
Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29:4741–4751
Onder TT, Gupta PB, Mani SA, Yang J, Lander ES, Weinberg RA (2008) Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68:3645–3654
Zhang WC, Shyh-Chang N, Yang H, Rai A, Umashankar S, Ma S et al (2012) Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148:259–272
Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T, Oyama T (2010) Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 30:2513–2517
Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J et al (2010) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Zhongguo Fei Ai Za Zhi 13:171–189
Kusumbe AP, Bapat SA (2009) Cancer stem cells and aneuploid populations within developing tumors are the major determinants of tumor dormancy. Cancer Res 69:9245–9253
Kim EY, Lee SS, Shin JH, Kim SH, Shin DH, Baek SY (2014) Anticancer effect of arsenic trioxide on cholangiocarcinoma: in vitro experiments and in vivo xenograft mouse model. Clin Exp Med 14:215–224
Patel P, Chen EI (2012) Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne) 3:125
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444:756–760
Mimeault M, Batra SK (2011) Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy. Chin Med 6:31
Liu C, Tang DG (2011) MicroRNA regulation of cancer stem cells. Cancer Res 71:5950–5954
Yu Y, Sarkar FH, Majumdar AP (2013) Down-regulation of miR-21 induces differentiation of chemoresistant colon cancer cells and enhances susceptibility to therapeutic regimens. Transl Oncol 6:180–186
Sarkar FH, Li Y, Wang Z, Kong D, Ali S (2010) Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist Updat 13:57–66
Incoronato M, Garofalo M, Urso L, Romano G, Quintavalle C, Zanca C et al (2010) miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res 70:3638–3646
Turrini E, Haenisch S, Laechelt S, Diewock T, Bruhn O, Cascorbi I (2012) MicroRNA profiling in K-562 cells under imatinib treatment: influence of miR-212 and miR-328 on ABCG2 expression. Pharmacogenet Genomics 22:198–205
Rui W, Bing F, Hai-Zhu S, Wei D, Long-Bang C (2010) Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1). J Cell Mol Med 14:206–214
Ahmad A, Aboukameel A, Kong D, Wang Z, Sethi S, Chen W et al (2011) Phosphoglucose isomerase/autocrine motility factor mediates epithelial-mesenchymal transition regulated by miR-200 in breast cancer cells. Cancer Res 71:3400–3409
Ahmad A, Maitah MY, Ginnebaugh KR, Li Y, Bao B, Gadgeel SM et al (2013) Inhibition of Hedgehog signaling sensitizes NSCLC cells to standard therapies through modulation of EMT-regulating miRNAs. J Hematol Oncol 6:77
Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H et al (2004) Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64:3753–3756
Takezawa K, Okamoto I, Tanizaki J, Kuwata K, Yamaguchi H, Fukuoka M et al (2010) Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther 9:1647–1656
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039–1043
Garofalo M, Croce CM (2013) MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat 16:47–59
Garofalo M, Romano G, Di LG, Nuovo G, Jeon YJ, Ngankeu A et al (2012) EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 18:74–82
Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE et al (2007) p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 17:1298–1307
Basak SK, Veena MS, Oh S, Lai C, Vangala S, Elashoff D et al (2013) The CD44(high) tumorigenic subsets in lung cancer biospecimens are enriched for low miR-34a expression. PLoS One 8, e73195
Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D et al (2010) Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res 70:5923–5930
Bao B, Ali S, Kong D, Sarkar SH, Wang Z, Banerjee S et al (2011) Anti-tumor activity of a novel compound-CDF is mediated by regulating miR-21, miR-200, and PTEN in pancreatic cancer. PLoS One 6, e17850
Jiang M, Zhang P, Hu G, Xiao Z, Xu F, Zhong T et al (2013) Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients. Mol Cell Biochem 383:67–75
Iliopoulos D, Lindahl-Allen M, Polytarchou C, Hirsch HA, Tsichlis PN, Struhl K (2010) Loss of miR-200 inhibition of Suz12 leads to polycomb-mediated repression required for the formation and maintenance of cancer stem cells. Mol Cell 39:761–772
Dandawate P, Padhye S, Ahmad A, Sarkar FH (2013) Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv Transl Res 3:165–182
Soubani O, Ali AS, Logna F, Ali S, Philip PA, Sarkar FH (2012) Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer. Carcinogenesis 33:1563–1571
Ichite N, Chougule MB, Jackson T, Fulzele SV, Safe S, Singh M (2009) Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res 15:543–552
Rahimi M, Huang KL, Tang CK (2010) 3,3′-Diindolylmethane (DIM) inhibits the growth and invasion of drug-resistant human cancer cells expressing EGFR mutants. Cancer Lett 295:59–68
Xue L, Firestone GL, Bjeldanes LF (2005) DIM stimulates IFNgamma gene expression in human breast cancer cells via the specific activation of JNK and p38 pathways. Oncogene 24:2343–2353
Hsu EL, Chen N, Westbrook A, Wang F, Zhang R, Taylor RT et al (2008) CXCR4 and CXCL12 down-regulation: a novel mechanism for the chemoprotection of 3,3′-diindolylmethane for breast and ovarian cancers. Cancer Lett 265:113–123
Jung MJ, Rho JK, Kim YM, Jung JE, Jin YB, Ko YG et al (2013) Upregulation of CXCR4 is functionally crucial for maintenance of stemness in drug-resistant non-small cell lung cancer cells. Oncogene 32:209–221
Ye MX, Li Y, Yin H, Zhang J (2012) Curcumin: updated molecular mechanisms and intervention targets in human lung cancer. Int J Mol Sci 13:3959–3978
Zhang H, Yu T, Wen L, Wang H, Fei D, Jin C (2013) Curcumin enhances the effectiveness of cisplatin by suppressing CD133 cancer stem cells in laryngeal carcinoma treatment. Exp Ther Med 6:1317–1321
Mimeault M, Batra SK (2014) Altered gene products involved in the malignant reprogramming of cancer stem/progenitor cells and multitargeted therapies. Mol Aspects Med 39:3–32
Zhang J, Zhang T, Ti X, Shi J, Wu C, Ren X et al (2010) Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem Biophys Res Commun 399:1–6
Zhang J, Du Y, Wu C, Ren X, Ti X, Shi J et al (2010) Curcumin promotes apoptosis in human lung adenocarcinoma cells through miR-186* signaling pathway. Oncol Rep 24:1217–1223
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Suresh, R., Ali, S., Ahmad, A., Philip, P.A., Sarkar, F.H. (2016). The Role of Cancer Stem Cells in Recurrent and Drug-Resistant Lung Cancer. In: Ahmad, A., Gadgeel, S. (eds) Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Advances in Experimental Medicine and Biology, vol 890. Springer, Cham. https://doi.org/10.1007/978-3-319-24932-2_4
Download citation
DOI: https://doi.org/10.1007/978-3-319-24932-2_4
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-24931-5
Online ISBN: 978-3-319-24932-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)